Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer.
Xiao-Xiao PengRuoying YuXue WuShu-Yu WuCan PiZhi-Hong ChenXu-Chao ZhangCun-Yi GaoYang W ShaoLi LiuYi-Long WuQing ZhouPublished in: Journal for immunotherapy of cancer (2021)
Patients with NSCLC represent unique plasma exosomal miRNA profiles. Hsa-miR-320d, hsa-miR-320c, and hsa-miR-320b were identified as potential biomarkers for predicting the efficacy of immunotherapy in advanced NSCLCs. When T-cell suppressor hsa-miR-125b-5p was downregulated during the treatment, the patients may obtain increased T-cell function and respond well to immunotherapy.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- cell proliferation
- small cell lung cancer
- wild type
- end stage renal disease
- long non coding rna
- ejection fraction
- long noncoding rna
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- patient reported